Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis

BMJ

Volumn 326, Issue 7384, 2003, Pages 334-

  Sterchi, Rebekka ^a   Dieppe, Paul ^b   Metcalfe, Scott ^c   Dougherty, Sean ^c   McNee, Wayne ^c   Deeks, jonathan J ^d   Bradley, Matthew D ^e  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c Pharmaceutical Management Agency   (New Zealand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007763121     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.326.7384.334     Document Type: Article

References (15)

1. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 619–623
2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 284: 1247–1255
3. Jüni P, Rutjes AW, Dieppe P. Are selective COX 2 inhibitors superior to traditional NSAIDs? BMJ 2002; 325: 163–164. (20 July.)
4. Jüni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287–1288
5. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 619–623
6. Jones R. Efficacy and safety of COX 2 inhibitors. BMJ 2002; 325: 607–608
7. Witter J. Celebrex capsules (celecoxib). Medical officer review. US Department of Health and Human Services Food and Drug Administration, 2000. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_03_med.pdf (accessed I Jun 2002).
8. Lu HL. Celebrex capsules (celecoxib). Statistical reviewer briefing document for the advisory committee. US Department of Health and Human Services Food and Drug Administration, 2000. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.doc (accessed 1 Jun 2002).
9. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287–1288
10. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 284: 1247–1255
11. Juni P, Rutjes AW, Dieppe P. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287–1288
12. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 619–623
13. Witter J. Celebrex capsules (celecoxib). Medical officer review. US Department of Health and Human Services Food and Drug Administration, 2000. http://www.fda.gov/dockets/ac/01/briefing/3677b1_03_med.pdf (accessed 1 Jun 2002).
14. Lu HL. Celebrex capsules (celecoxib). Statistical reviewer briefing document for the advisory committee. US Department of Health and Human Services Food and Drug Administration, 2000. http://www.fda.gov/dockets/ac/01/briefing/3677b1_04_stats.doc (accessed 1 Jun 2002).
15. Deeks JJ. Study reports: clarification, corrections, and additional sources. Electronic response to: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis. bmj.com 2002. http://bmj.com/cgi/eletters/325/7365/619#26882 (accessed 30 Dec 2002).